Fallopian tube cancer is rare, accounting for about 1% of gynecologic cancers. It behaves much like ovarian cancer and is now often grouped with it under the umbrella of high-grade serous carcinoma. Most cases are found at advanced stages, when cancer has spread beyond the tubes, and treatment typically involves surgery followed by platinum-based chemotherapy.
What's actually going on in research
Trials are testing PARP inhibitors for BRCA-mutated cancers, antibody-drug conjugates that deliver chemotherapy directly to tumor cells, immune checkpoint inhibitors alone and combined with chemotherapy, and new platinum doublets. Researchers are also studying earlier detection methods and whether removing fallopian tubes in high-risk women prevents cancer.
PARP inhibitors
Olaparib and other PARP inhibitors are FDA-approved for maintenance after chemotherapy in BRCA-mutated ovarian and fallopian tube cancers. Trials are testing them in earlier treatment lines and in combination with other drugs.
Antibody-drug conjugates
Mirvetuximab soravtansine was approved in 2022 for folate receptor-alpha positive cancers. Other antibody-drug conjugates are in trials, aiming to deliver chemotherapy more precisely to cancer cells while sparing healthy tissue.
Immunotherapy combinations
Checkpoint inhibitors haven't worked well alone in most ovarian and fallopian tube cancers. Trials are testing them combined with chemotherapy, PARP inhibitors, or VEGF inhibitors to see if combinations overcome resistance.
What to know before you search
Eligibility typically depends on cancer stage, BRCA or HRD mutation status, how recently you completed chemotherapy, and whether your cancer is platinum-sensitive or platinum-resistant.
What types of trials are currently open
- Maintenance trials — Testing drugs like PARP inhibitors or immunotherapy given after chemotherapy to keep cancer from returning or progressing.
- Combination trials — Studies pairing chemotherapy with targeted drugs like bevacizumab or checkpoint inhibitors to improve initial treatment response.
- Recurrence trials — Testing new drugs or combinations for cancers that have returned after prior treatment, often focusing on platinum-resistant disease.
- Biomarker trials — Enrolling people based on tumor features like BRCA mutations, HRD status, or folate receptor expression to test matched therapies.
- Prevention trials — Studying whether removing fallopian tubes in women at high genetic risk prevents cancer from developing.
Recently added Fallopian Tube Cancer trials
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm. The goal of this observational study is to collect real-world data on treatment patterns, clinical effectiveness, participant characteristics, biomarker testing, and health-related quality of life in participants with FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer receiving mirvetuximab soravtansine. Mirvetuximab soravtansine (MIRV) is an approved antibody-drug conjugate being studied for the treatment of FRα-positive platinum-resistant ovarian, fallopian tube, and peritoneal cancer. Adult participants with FRα-positive platinum-resistant cancer who have received 1-3 prior treatment lines and are scheduled to receive MIRV as monotherapy will be enrolled. Approximately 500 participants will be enrolled at sites globally. Participants will receive intravenous infusions of mirvetuximab soravtansine as monotherapy according to the local product label and treating physician's decision. The total study duration per participant may be up to 18 months of follow-up. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic Lesions
OLIGYNE-10 RT is an international registry of adults with gynecologic cancer and a limited number of active sites of cancer spread who receive radiotherapy (RT) to at least one metastatic lesion during routine care. The registry combines information from existing medical records with information collected prospectively. Treating clinical teams choose radiotherapy, imaging, systemic treatment, and follow-up. The registry does not assign treatment or require additional imaging or visits. The classical cohort includes people with 1 to 5 active metastatic lesions assessed by computed tomography (CT) or magnetic resonance imaging (MRI), with or without positron emission tomography (PET). An extended, exploratory cohort includes people with 6 to 10 active metastatic lesions assessed by qualifying fluorodeoxyglucose (FDG) positron emission tomography (PET) with computed tomography (CT) or magnetic resonance imaging (MRI). Eligible cancers include cervical, endometrial and other uterine cancers, uterine sarcomas, ovarian and fallopian tube cancers, primary peritoneal cancers, vulvar and vaginal cancers, and other eligible rare gynecologic cancers. The main objective is to describe the time from the first qualifying radiotherapy session or brachytherapy application until imaging shows cancer progression at any site or the participant dies. Other objectives include describing the control of treated lesions, patterns of cancer progression, survival, side effects, subsequent treatment of metastases, and how radiotherapy relates to the continuation or change of systemic treatment. The initial target is 500 participants, with possible expansion to at least 1,000. Follow-up is planned for up to five years using information available from routine care.
Find Fallopian Tube Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.